Theravance Biopharma (NASDAQ:TBPH) Issues Earnings Results

Theravance Biopharma (NASDAQ:TBPH) released its earnings results on Thursday. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.13), FiscalAI reports. Theravance Biopharma had a return on equity of 19.58% and a net margin of 104.34%.The firm had revenue of $17.70 million for the quarter, compared to the consensus estimate of $17.78 million.

Theravance Biopharma Trading Down 0.1%

Shares of TBPH traded down $0.01 during trading hours on Friday, reaching $17.01. 237,595 shares of the company traded hands, compared to its average volume of 351,599. The stock’s fifty day moving average price is $15.79 and its 200 day moving average price is $17.37. The firm has a market cap of $876.19 million, a price-to-earnings ratio of 7.73 and a beta of 0.19. Theravance Biopharma has a 12-month low of $8.33 and a 12-month high of $21.03.

Wall Street Analyst Weigh In

A number of research firms have commented on TBPH. B. Riley Financial raised their target price on shares of Theravance Biopharma from $14.00 to $17.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 7th. Oppenheimer cut shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 5th. Zacks Research upgraded shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Thursday, March 19th. Wall Street Zen cut shares of Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 2nd. Finally, TD Cowen raised their target price on shares of Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a research note on Monday, March 23rd. Two analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $21.83.

Insider Activity

In other news, SVP Rhonda Farnum sold 31,067 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $13.96, for a total transaction of $433,695.32. Following the transaction, the senior vice president owned 232,699 shares in the company, valued at $3,248,478.04. This represents a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 6.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Theravance Biopharma

A number of large investors have recently bought and sold shares of TBPH. Quarry LP acquired a new position in Theravance Biopharma in the 3rd quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd increased its holdings in Theravance Biopharma by 107.4% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 1,411 shares during the period. CIBC Private Wealth Group LLC increased its holdings in Theravance Biopharma by 20,269.6% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after buying an additional 4,662 shares during the period. Tower Research Capital LLC TRC increased its holdings in Theravance Biopharma by 18.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 781 shares during the period. Finally, Virtus Advisers LLC acquired a new position in Theravance Biopharma in the 4th quarter worth approximately $170,000. Hedge funds and other institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.